BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
作者： Kamil Bojarczuk , Binu K. Sasi , Stefania Gobessi , Idanna Innocenti , Gabriele Pozzato
DOI: 10.1182/BLOOD-2015-10-675009
关键词:
摘要: The Bcl-2 antagonist ABT-199 (venetoclax) has demonstrated promising clinical activity in patients with chronic lymphocytic leukemia (CLL). is strongly cytotoxic against unstimulated peripheral blood CLL cells vitro but much less effective that have received survival
ashpublications.org
core.ac.uk
bloodjournal.org参考文章(47)
S Jilg, V Reidel, C Müller-Thomas, J König, J Schauwecker, U Höckendorf, C Huberle, O Gorka, B Schmidt, R Burgkart, J Ruland, HJ Kolb, C Peschel, RAJ Oostendorp, KS Götze, PJ Jost, None, Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. ,vol. 30, pp. 112- 123 ,(2016) , 10.1038/LEU.2015.179
R. Thijssen, E. Slinger, K. Weller, C. R. Geest, T. Beaumont, M. H. J. van Oers, A. P. Kater, E. Eldering, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors Haematologica. ,vol. 100, ,(2015) , 10.3324/HAEMATOL.2015.124560
Maria Fernanda Pascutti, Margot Jak, Jacqueline M. Tromp, Ingrid A. M. Derks, Ester B. M. Remmerswaal, Rachel Thijssen, Martijn H. A. van Attekum, Gregor G. van Bochove, Dieuwertje M. Luijks, Steven T. Pals, René A. W. van Lier, Arnon P. Kater, Marinus H. J. van Oers, Eric Eldering, IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells Blood. ,vol. 122, pp. 3010- 3019 ,(2013) , 10.1182/BLOOD-2012-11-467670
Jonathan W. Friedberg, Jeff Sharman, John Sweetenham, Patrick B. Johnston, Julie M. Vose, Ann LaCasce, Julia Schaefer-Cutillo, Sven De Vos, Rajni Sinha, John P. Leonard, Larry D. Cripe, Stephanie A. Gregory, Michael P. Sterba, Ann M. Lowe, Ronald Levy, Margaret A. Shipp, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood. ,vol. 115, pp. 2578- 2585 ,(2010) , 10.1182/BLOOD-2009-08-236471
A. Cimmino, G. A. Calin, M. Fabbri, M. V. Iorio, M. Ferracin, M. Shimizu, S. E. Wojcik, R. I. Aqeilan, S. Zupo, M. Dono, L. Rassenti, H. Alder, S. Volinia, C.-g. Liu, T. J. Kipps, M. Negrini, C. M. Croce, miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 13944- 13949 ,(2005) , 10.1073/PNAS.0506654102
T Ni Chonghaile, A Letai, Mimicking the BH3 domain to kill cancer cells. Oncogene. ,vol. 27, ,(2008) , 10.1038/ONC.2009.52
S Gobessi, L Laurenti, P G Longo, L Carsetti, V Berno, S Sica, G Leone, D G Efremov, Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia. ,vol. 23, pp. 686- 697 ,(2009) , 10.1038/LEU.2008.346
Kumudha Balakrishnan, Varsha Gandhi, Bcl-2 antagonists: a proof of concept for CLL therapy. Investigational New Drugs. ,vol. 31, pp. 1384- 1394 ,(2013) , 10.1007/S10637-013-0002-4
Meike Vogler, Michael Butterworth, Aneela Majid, Renata J. Walewska, Xiao-Ming Sun, Martin J. S. Dyer, Gerald M. Cohen, Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. ,vol. 113, pp. 4403- 4413 ,(2009) , 10.1182/BLOOD-2008-08-173310
W J M Mackus, A P Kater, A Grummels, L M Evers, B Hooijbrink, M H H Kramer, J E Castro, T J Kipps, R A W van Lier, M H J van Oers, E Eldering, Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia. ,vol. 19, pp. 427- 434 ,(2005) , 10.1038/SJ.LEU.2403623